FDA Approves Generic Drug to Treat Allergic Dermatitis in Cats
Sponsored by Provetica, Modulis for Cats contains the same active ingredient, concentration and dosage form as the Atopica for Cats brand product.
Officials with the FDA have approved1 Modulis for Cats, the first generic cyclosporine oral solution for companion felines, sponsored by Provetica LLC. It contains the same active ingredient in the same concentration and dosage form as the Atopica for Cats brand product by Elanco.
Cyclosporine oral solution for cats is indicated for the control of certain skin conditions resulting from feline allergic dermatitis. Cats with feline allergic dermatitis may be intensely itchy and lick, chew and scratch at their skin and hair. As a result, affected cats can develop excoriations because of the cat scratching itself, miliary dermatitis, skin lesions, and self-induced hair loss.
Modulis for Cats is an immunosuppressant drug that suppresses the allergic process that causes cats with this condition to be itchy. The drug is intended for use in cats at least 6 months of age and at least 3 lbs in body weight. It is supplied in 4.7-, 15-, and 30-mL glass amber bottles and is only available by prescription from a licensed veterinarian.
People handling, administering, or exposed to cyclosporine oral solution for cats should take precautions to avoid accidentally ingesting the drug, such as not eating, drinking, smoking or using smokeless tobacco while handling it, according to the FDA. Users should also wash hands after administration of this product. People with known hypersensitivity to cyclosporine should avoid contact with the product.
Atopica for Cats was first approved by the FDA on August 8, 2011.
This article originally appeared on dvm360.
Reference
